

EMA/282640/2023

European Medicines Agency decision P/0276/2023

of 14 July 2023

on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMA-001526-PIP01-13-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0276/2023

of 14 July 2023

on the acceptance of a modification of an agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), (EMA-001526-PIP01-13-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0205/2014 issued on 8 August 2014, the decision P/0255/2015 issued on 30 October 2015, the decision P/0325/2017 issued on 31 October 2017 the decision P/0136/2019 issued on 17 April 2019, the decision P/0460/2020 issued on 4 December 2020 and the decision P/0369/2021 issued on 8 September 2021,

Having regard to the application submitted by Takeda Pharmaceuticals International AG Ireland Branch on 16 February 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 May 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for recombinant parathyroid hormone (Natpar), powder and solvent for solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Takeda Pharmaceuticals International AG Ireland Branch, Block 2 Miesian Plaza, 50-58 Baggot Street Lower, 2 – Dublin, Ireland.

EMA/PDCO/96246/2023 Corr. ¹
Amsterdam, 26 May 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001526-PIP01-13-M06

Scope of the application

Active substance(s):

Recombinant parathyroid hormone

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of hypoparathyroidism

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Takeda Pharmaceuticals International AG Ireland Branch

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Takeda Pharmaceuticals International AG Ireland Branch submitted to the European Medicines Agency on 16 February 2023 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0205/2014 issued on 8 August 2014, the decision P/0255/2015 issued on 30 October 2015, the decision P/0325/2017 issued on 31 October 2017 the decision P/0136/2019 issued on 17 April 2019, the decision P/0460/2020 issued on 4 December 2020 and the decision P/0369/2021 issued on 8 September 2021.

¹ 13 July 2023

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 March 2023.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of hypoparathyroidism

2.1.1. Indication(s) targeted by the PIP

Long-term treatment of subjects with hypoparathyroidism

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of lower strength of existing dose form and age-appropriate delivery device for use in children from birth to less than 12 years of age
Non-clinical studies	Study 2 Repeat-dose toxicity study in juvenile rats, including bone densitometry, histomorphometry and histopathology, plus femur and tibia length
Clinical studies	Study 3: <i>deleted and combined with study 5 in procedure EMEA-001526-PIP01-13-M05</i> Study 4: <i>deleted and combined with study 3 in procedure EMEA-001526-PIP01-13-M03</i> Study 5 Open-label, non-controlled trial to assess pharmacokinetics, pharmacodynamics, safety and activity of recombinant parathyroid hormone, administered with age-appropriate delivery device as add-on to best standard of care in children and adolescents from birth to less than 18 years of age with hypoparathyroidism

	Study 6: <i>deleted and combined with study 5 in procedure EMEA-001526-PIP01-13-M03</i>
Extrapolation, modelling and simulation studies	Study 7 Development of a population PK model and quantitative system pharmacology model (QSP) to perform simulations and to support the choice of doses for the studies in children from birth to less than 18 years of age
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of hypoparathyroidism

Authorised indication(s):

- as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
 - Invented name(s): Natpar
 - Authorised pharmaceutical form(s): Powder and solvent for solution for injection
 - Authorised route(s) of administration: Subcutaneous use
 - Authorised via centralised procedure